Zobrazeno 1 - 10
of 2 394
pro vyhledávání: '"immune related adverse event"'
Autor:
Takashi Hatori, Takeshi Numata, Toshihiro Shiozawa, Manato Taguchi, Hirofumi Sakurai, Tomohiro Tamura, Jun Kanazawa, Hiroaki Tachi, Kyoko Kondo, Kunihiko Miyazaki, Norihiro Kikuchi, Koichi Kurishima, Hiroaki Satoh, Nobuyuki Hizawa
Publikováno v:
Current Oncology, Vol 31, Iss 11, Pp 6502-6511 (2024)
Background: This study aimed to investigate prognostic factors for predicting the survival of patients with extensive-disease-stage small-cell lung cancer treated with chemoimmunotherapy. Methods: Patients were classified according to overall surviva
Externí odkaz:
https://doaj.org/article/0f2fb04bc9704576b86f50792c6d0c88
Autor:
Courtney M. Kenyon, BS, Brenna G. Kelly, MD, Anneli R. Bowen, MD, Matthew Gumbleton, MD, PhD, Dekker C. Deacon, MD, PhD
Publikováno v:
JAAD Case Reports, Vol 52, Iss , Pp 34-37 (2024)
Externí odkaz:
https://doaj.org/article/898132e9eff94fb3a0010d3ed2b9eca4
Autor:
Takahisa Niimoto, Takafumi Todaka, Hirofumi Kimura, Shotaro Suzuki, Shumpei Yoshino, Kosuke Hoashi, Hirotaka Yamaguchi
Publikováno v:
International Journal of Emergency Medicine, Vol 17, Iss 1, Pp 1-10 (2024)
Abstract Background Cytokine release syndrome (CRS) is an acute systemic inflammatory syndrome characterized by fever and multiple organ failure, which is triggered by immunotherapy or certain infections. Immune checkpoint inhibitors rarely cause imm
Externí odkaz:
https://doaj.org/article/7455da7d0bef4278a6051207694f8e5c
Publikováno v:
Case Reports in Oncology, Vol 17, Iss 1, Pp 966-972 (2024)
Introduction: Immune-related adverse events (irAEs) from nivolumab can affect any organ, but renal impairment is less common than effects on other organs. We encountered a case in which a renal irAE was difficult to diagnose due to mild renal dysfunc
Externí odkaz:
https://doaj.org/article/dbc979ba0f524722bd33649ea400481f
Autor:
Akira Sugimoto, Hiroyasu Kaneda, Naoki Yoshimoto, Kenji Nagata, Tatsuo Fujii, Koichi Michimoto, Shunsuke Ueno, Takao Kamimori, Yoshie Ishii, Mai Sakagami, Haruo Inokuchi, Keiko Shibuya, Megumi Mizutani, Hiroaki Nagamine, Kenji Nakahama, Yoshiya Matsumoto, Yoko Tani, Kenji Sawa, Tomoya Kawaguchi
Publikováno v:
Scientific Reports, Vol 14, Iss 1, Pp 1-11 (2024)
Abstract The usefulness of the derived neutrophil-to-lymphocyte ratio (dNLR) and its dynamics before/after durvalumab consolidation therapy to predict safety or efficacy remains unclear. We retrospectively reviewed patients with locally advanced non-
Externí odkaz:
https://doaj.org/article/a1e3dc2e879d4326860faa2cdb518933
Autor:
Luise A. Roser, Charline Sommer, Samira Ortega Iannazzo, Christina Sakellariou, Zoe Waibler, Patricia Gogesch
Publikováno v:
Journal of Immunotoxicology, Vol 21, Iss sup1, Pp S38-S47 (2024)
Interleukin-2 (IL-2) was one of the first cytokines discovered and its central role in T cell function soon led to the notion that the cytokine could specifically activate immune cells to combat cancer cells. Recombinant human IL-2 (recIL-2) belonged
Externí odkaz:
https://doaj.org/article/30b72627c34e481289f3cb73c5bfb48d
Autor:
Camille M. Powers, Hannah Verma, Jeremy Orloff, Austin J. Piontkowski, Amy Tiersten, Angela Lamb, Nicholas Gulati
Publikováno v:
Journal of Dermatological Treatment, Vol 35, Iss 1 (2024)
In this report, we describe the case of a 28-year-old female with bilateral breast cancer in the setting of a BRCA1 mutation, who presented to dermatology with an eczematous reaction, ultimately diagnosed as a cutaneous immune-related adverse event (
Externí odkaz:
https://doaj.org/article/5b1c63d1de0a4d988d46bd8975dac0fa
Publikováno v:
Frontiers in Immunology, Vol 15 (2024)
BackgroundThe advent of immune checkpoint inhibitors (ICIs) has revolutionized the treatment landscape for tumor patients, dramatically improving survival rate. However, patients treated with immunotherapy are inevitably at risk of immune-related adv
Externí odkaz:
https://doaj.org/article/d23cafd72fe64319bc9bc5abc87b7b8d
Publikováno v:
Journal of Cutaneous Immunology and Allergy, Vol 7 (2024)
Externí odkaz:
https://doaj.org/article/2157a2c3008f49b39279d43ed1746efe
Publikováno v:
Journal of Cancer Research and Practice, Vol 11, Iss 2, Pp 81-84 (2024)
Nivolumab is now preferred as first-line and second-line treatment for advanced esophageal cancer, while regorafenib improves survival in refractory gastroesophageal cancer. The combined use of nivolumab and regorafenib has shown promising results. N
Externí odkaz:
https://doaj.org/article/db3c2a84052442efa13d4684e9528712